Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for Large Thyroid Nodules

NCT ID: NCT07046546

Last Updated: 2025-12-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-29
• Study Completion Date: 2027-05-31

Brief Summary

Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery. Not all patients are suitable however for these treatments, some lumps are too large, or the patients are not fit enough for surgery.

Thyroid artery embolization (TAE) is a new minimally invasive technique (smaller incisions / cuts and shorter recovery time) performed under light sedation. It is used by other European Thyroid Centres, but it hasn't been used in the UK. Embolization means arteries supplying the thyroid gland are blocked by injecting small occlusive particles, like very fine grains of sand that can get stuck in small spaces, preventing blood from passing through. Blocking the thyroid arteries causes the gland to shrink. This provides symptom relief or controls an overactive gland.

We aim to undertake a TAE pilot study to explore the safety of TAE in a UK patient population. We are planning to recruit 10 eligible patients. We will also collect additional data (for example on pain, effectiveness, cost and health related quality of life) to inform a future larger trial comparing TAE to other treatment options.

Detailed Description

Justification:

Large thyroid nodules in the neck can cause local pressure symptoms and cosmetic issues. Current treatment options include radioactive iodine (RAI), radiofrequency ablation (RFA) and surgery but larger nodules are difficult to shrink or remove and are associated with risks that some patients find unacceptable such as an underactive thyroid gland which requires life long tablets and surgical scars. Larger nodules are also more difficult to remove surgically.

Thyroid artery embolisation (TAE) is a new procedure for non-cancerous thyroid nodules which are causing local symptoms or hyperthyroidism (overactive thyroid glands). TAE involves blocking thyroid arteries using tiny particles introduced via a small tube (catheter). The tube is guided to the thyroid artery under x-ray guidance. In published studies TAE has been used in small numbers of patients with large thyroid glands where other treatment options are difficult. Evidence shows TAE is safe and improves thyroid function in patients with an overactive gland. TAE also causes gland shrinkage (between 40% to 70%) and improves local neck symptoms (like tightness or pressure), cosmetic appearance and quality of life.

Early research indicates TAE is promising but wider use of the procedure is limited by a lack of high-quality research with larger numbers of patients. It has also never been evaluated in the NHS or UK. We therefore aim to undertake the first UK feasibility study into TAE to primarily evaluate safety. This study will help inform a future larger trial to understand how effective TAE is.

Methodology:

Single site study at Royal Berkshire NHS Foundation Trust.

10 patients will be recruited to the study. Participants will have been diagnosed with an enlarged thyroid gland which is causing local neck symptoms (e.g. pressure or tightness), cosmetic issues or thyroid overactivity.

1. Patient will be first seen and assessed by the ENT team or Interventional Radiology Consultants who confirm the patient has non-cancerous thyroid nodules and requires treatment for their thyroid disease. This is standard care.

2. All patients are then seen by the ENT team (if not already seen). The ENT team consider whether the patient is suitable for study inclusion and discuss possible study participation with the patient. The ENT team provide a study patient information sheet (PIS) and after care advice sheet at this time. With the patients permission the ENT team provides the patients contact details to the research study team (via hospital email or electronic messaging). The ENT team will also document study discussion in the patients electronic records. (10 minutes)

3. Study team contacts the patient by telephone and discusses the study. Patient questions addressed. Telephone consent obtained. Patient sent a copy of the consent form prior to their study pre-assessment clinic (by email or paper form by post). (20 minutes)

If individuals require more time to consider participation they will be contacted again at an agreed time.

4. Potential participants will attend a screening visit in the Interventional Radiology department at RBFT. The following investigations would then be performed / arranged: ultrasound, needle tests of thyroid gland, CT and blood tests.

(40 minutes).

5. Study team (principle investigator) assesses all results of the screening visit. If the patient meets study inclusion criteria, study team (research nurse) liaises with Radiology booking team and arranges TAE treatment date. Patient and GP informed by letter/email. Patient will be sent a quality of life questionnaire by post or email (30 minutes).

If any results indicate TAE is unsuitable (e.g. abnormal needle test result) the patient will be referred back to the ENT team for standard care.

6. Study intervention (TAE) performed. (3 hours which includes arrival, admission and procedure time).

(Please note an external expert who is highly experienced in TAE will be present for the first two cases. They will only observe and advise where necessary)

9. Patient monitored in Radiology recovery area for 4 hours after procedure (4 hours)

10. Patient admitted to ENT ward for overnight observations and then discharged by research team the following day (approximately 16 to 24 hours)

11. One week post procedure telephone appointment: Analgesia questionnaire and adverse event score completed (can also be sent by post or email and returned by post or email if required). (30 minutes)

12. 3 months post procedure appointment: Quality of life questionnaires; Local symptom and cosmetic scores (out of 10); Thyroid function blood tests; Thyroid volume on ultrasound or CT arranged if required (1h)

13. 6 months post procedure appointment: Quality of life questionnaires; Local symptom and cosmetic scores (out of 10); Thyroid function tests; Thyroid volume on ultrasound or CT arrange if required (1h)

(Please note clinical assessment / evaluations will be undertaken outside these time points if clinically indicated).

Conditions

Thyroid Nodule (Benign); Graves Disease; Goitre

Keywords

Thyroid artery embolisation; Benign thyroid nodules

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Thyroid artery embolization treatment

Patient undergoing thyroid artery embolization

Group Type: EXPERIMENTAL

Thyroid artery embolization

Intervention Type: PROCEDURE

A minimally invasive procedure where one or more thyroid arteries are occluded to shrink the thyroid gland or thyroid nodules

Interventions

Thyroid artery embolization

A minimally invasive procedure where one or more thyroid arteries are occluded to shrink the thyroid gland or thyroid nodules

Intervention Type: PROCEDURE

Other Intervention Names

TAE

Eligibility Criteria

Inclusion Criteria

• The participant may enter the study if ALL of the following apply:

• Adults over 18 years of age willing and able to give informed consent.
• Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).
• Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre
• TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.
• FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.
• No enlarged / suspicious neck lymphadenopathy on ultrasound.
• Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and / or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.
• Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.

Exclusion Criteria

• The participant may enter the study if ALL of the following apply:

• Adults over 18 years of age willing and able to give informed consent.
• Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).
• Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre
• TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.
• FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.
• No enlarged / suspicious neck lymphadenopathy on ultrasound.
• Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and / or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.
• Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Reading

OTHER

Sponsor Role: collaborator

Royal Berkshire NHS Foundation Trust

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Royal Berkshire Hospital

Reading, , United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Farhan Ahmad

Role: CONTACT

Phone: +441183227936

Email: farhan.ahmad@royalberkshire.nhs.uk

Angelika Kristek

Role: CONTACT

Phone: +441183228223

Email: angelika.kristek@royalberkshire.nhs.uk

Facility Contacts

Ahmad Dr Farhan

Role: primary

Other Identifiers

IRAS338447

Identifier Type: -

Identifier Source: org_study_id